Vancomycin is an antibiotic of growing importance in the Background: treatment of hospital-acquired infections; with a particular emphasis on its value in the fight against Methicillin-resistant .
Introduction
The majority of admitted inpatients are given antimicrobials as therapy or prophylaxis during their hospitalization. It has been shown that at least 50% of antimicrobial prescriptions are unnecessary. Antimicrobial over prescription increases the costs of health care, increases super-infection due to antimicrobial-resistant bacteria, and may increase the likelihood of an unwanted side-effects 1 .
One critical challenge that health care faces is resistance to vancomycin, which is antibiotic that has a definite indications and a crucial role in treating infections in patients allergic to betalactam antibacterial medications or in bacterial infections that are resistant to other antibiotics 2 . Vancomycin acts by inhibiting the earlier stage of development of the bacterial cell wall compared to beta-lactams, it blocks cell wall phospholipid synthesis by inhibiting transglycosylase enzymes 3, 4 . Vancomycin has a narrow antibacterial spectrum against Methicillin-Resistant Staphylococcus aureus (MRSA), penicillin-resistant Enterococcus and Streptococcus pneumonia infections, thus is saved for these serious public health concerns [5] [6] [7] .
MRSA has become one of the predominant health care issues, and its resistance to vancomycin is growing. Cases of MRSA have increased in the US from 35.9% in 1992 to 64.4% in 2003, mainly due to inappropriate prescribing of broad spectrum antibiotics 8 . Additionally, 10 to 30% of nosocomial infections in US were caused by vancomycin-resistant enterococci (VRE) 9 . The increase in VRE has led to the development of recommendations for the use of vancomycin by the Hospital Infection Control Practices Advisory Committee (HICPAC) 10 , a part of the Centers for Disease Control and Prevention (CDC), published in 1995. They indicate what constitutes appropriate and inappropriate usage of vancomycin, and advises physicians to use the guidelines to decrease the emergence of vancomycin-resistant strains 11 .
Drug utilization evaluation (DUE) studies have an important role in controlling rational use of antibiotics to prevent resistance 9 . Since we did not have any data regarding how rationally vancomycin is being prescribed in Jafar Ibn Auf Pediatric Hospital, we conducted this DUE study to determine the rate of rational use of vancomycin according to the standard guidelines.
Methods

Study design and setting
We performed a retrospective cross-sectional record-based study of vancomycin use in Jafar Ibn Auf Pediatric Hospital, Khartoum, Sudan. From January 2018 to June 2018
Participants and study size Medical records of all patients hospitalized during the study period were reviewed.
Inclusion criteria included: any pediatric patients receiving vancomycin during their hospitalization.
Exclusion criteria included: patients who received vancomycin orally because the infusion rate is one of the variables that should be measured and/or patients with incomplete data.
Variables
Medical records were reviewed, and the following data was extracted using a check list (see extended data 12 ): dose of vancomycin; duration of infusion; duration of treatment with vancomycin; serum creatinine monitoring; culture and sensitivity test results; concurrent antimicrobials and nephrotoxic drugs; and adverse drug reactions.
Data sources/ measurements
The study was carried out by reviewing all medical records of patients who were admitted and received vancomycin during the study period. A data collection form was used to gather patients' information. Patients were grouped according to their age into: neonates (1-28 days), infants (1-24 month) and children (2-14 years) . Appropriate or inappropriate use of vancomycin was classified according to the guidelines issued by HICPAC. The reasons for appropriate use include: the treatment of β-lactams-resistant gram-positive infections, treatment of patients allergic to β-lactams with gram-positive infections, discontinuation of vancomycin therapy when microbial cultures are negative, and empiric therapy in patients with risk factors; such as patients with co-morbidities and intensive care unit patient's or confirmed gram-positive infections by culture. Cases in which the use was empiric in patients with risk factors has been justified by hospital epidemiology -due to a high prevalence of methicillin-resistant Staphylococcus aureus (MRSA).
Statistical analysis
Statistical analysis SPSS version 20.0 was used to analyze the data. Continuous variables were analyzed using Student's t-test. Chi-squire test was used to compare qualitative variables. P values less than 0.05 were considered to be statistically significant.
Ethical statement
Ethical clearance (FPEC-07-2018) was obtained from the Ethical Committee of the Faculty of Pharmacy, University of Khartoum. Additional approval for checking the medical records was obtained from Jafar Ibn Auf Pediatric Hospital.
Results
During the study period, 127 patients (61 females and 66 males) received vancomycin (Underlying data 12 ). As shown in Table 1 , about a quarter of patients were hospitalized in a period of 11 to 15 days. Culture tests were performed in 20.5% of patients, with blood being the most common sample taken for microbiology study. Moreover, about 38.6% of patients received vancomycin for 4 to 7 days. (Table 1) According to clinical indication, vancomycin was used to treat sepsis and pneumonia in 29% and 19.7% of patients respectively (Table 2 ). However, around 55% of patients had received vancomycin without specific instructions from physicians to the nurses regarding the duration of infusion, while 26.8% and 18.1% of patients were receiving vancomycin with specific instructions stated from the physician in the medical records to give vancomycin for duration of 1 hour or 30 min, respectively ( Table 2) .
Results for the monitoring of serum creatinine are presented in Table 3 . Appropriate dose (dosing and frequency) was observed in 81% of the patients (including renal dose adjustment), the need for dose adjustment was essential in 21 patients, but only 11 cases were adjusted. Recorded adverse drug reactions and drug-drug interactions are shown in Table 3 . Only 5% of patients developed nephrotoxicity, and furosemide was the most common prescribed drug recorded to have a potential drug-drug interaction.
According to the HICPAC guidelines, vancomycin use was considered appropriate in 86 participants (67.8%) ( Table 4 ). Of these, 27.6% of cases (35) were empiric therapy in patients with risk factors; such as patients with co-morbidities and intensive care unit patients. 22.8 % (29) was for the treatment of β-lactams-resistant gram-positive infections treatment, 12.6% (16) for confirmed gram positive infections by culture, 2.4% (3) for treatment of patients allergic to β-lactams with gram-positive infections and 2.4% (3) for discontinuation of vancomycin therapy when microbial cultures are negative. Moreover, there was a significant difference in the appropriateness of vancomycin use in the three groups based on age (neonates, infants and children), with P value= 0.015 (Table 4 ).
Discussion
Vancomycin is an antibiotic used to treat serious infections in patients hypersensitive to β-lactam antibiotics, or those caused by bacteria resistant to β-lactams such as MRSA 13 . In this study, sepsis (29%) and pneumonia (19.6%) were the most common indications for vancomycin use; a similar finding has been reported in Oman 14 . On the other hand, an Iranian study showed that vancomycin was mostly used to treat febrile neutropenia (87.9%) and sepsis (74.5%) 15 , which was similar to results reported in Hong Kong 16 . Considering the duration of vancomycin therapy, the maximum duration (40 days) was prescribed in one patient suffering from pneumonia; the minimum period of administration was one day. Most infections, including gram-positive bacteria, can be treated for less than 15 days with vancomycin, but the duration of treatment with vancomycin for endocarditis and osteomyelitis can last for up to an 8-week period 17 .
Our study demonstrated that most patients received vancomycin empirically without following culture and sensitivity According to the HICPAC guidelines, 67.7% of the vancomycin prescriptions were appropriate; the reasons for its appropriate use included the treatment of β-lactams-resistant gram-positive infections, treatment of patients allergic to β-lactams with gram-positive infections, and discontinuation of vancomycin therapy when microbial cultures have been negative. Empiric therapy is also in patients with risk factors and confirmed gram-positive infections by culture. The rate of adherence to HICPAC recommendations was lower in our study compared to other trials, including Alfandari et al. 19 and Melo et al. 20 studies, in which the rate of appropriate use was 71% and 95% respectively. However, in Askarian et al's study out of 200 vancomycin prescriptions, only 12 (6%) were considered appropriate 21 ; which was very low compared to our results.
Given the importance of infusion rate, and the occurrence of "red man syndrome" by vancomycin 22 (a hypersensitivity reaction characterized by flushing, erythema and pruritus, particularly of the upper body), the guidelines recommend that the time of infusion should be ≥ 30 minutes per 500 mg dose of vancomycin to avoid this infusion-related anaphylaxis-like reaction 23,24 . The results showed that in more than half of the patients (55%) there were no specific instructions regarding the duration of infusion. An anaphylactic reaction occurred in two patients.
Nephrotoxicity is one of the most common adverse drug reactions, so daily monitoring of serum creatinine and estimated creatinine clearance, in addition to ensuring the proper vancomycin dose can be effective while preventing renal toxicity 25,26 . Multiple risk factors influencing the occurrence of nephrotoxicity include; treatment duration beyond one week, preexisting renal insufficiency, concurrent administration of nephrotoxic drugs, sepsis and critical illnesses, as well as infusion rate 27,28 . In this study, nephrotoxicity occurred in 4.7% of patients, although serum creatinine testing was performed in 81% of patients.
Concerning serum creatinine monitoring, guidelines recommend that it should be monitored at least twice weekly, and weekly for long term therapy 29 . In this study, in 60.6% of patients;
serum creatinine was monitored once (75% of them before initiating vancomycin therapy and 25% during treatment with vancomycin therapy), while only 20% of patients were monitored twice weekly. 19% of cases had no serum creatinine monitoring. In Oliveira and Ribeiro's study, serum creatinine was monitored to 93.4% patients which was higher compared to our results 30 .
Regarding dosing of vancomycin; in neonates, 15mg/kg is the suggested starting dose, then 10 mg/kg every 12 hours up to the first week after birth, followed by 10 mg/kg every 8 hours up to the age of one month ;for children >1 month 15 mg/kg every 8 hours (maximum daily dose 2 g) is recommended 31 . Appropriate dosing was observed in 81% of the patients, which was higher than an Iranian study in which 52% of the participants were given an appropriate dose 18 . Since 80% to 90% of vancomycin is excreted unchanged in the urine, dose adjustment is required in renal insufficient/failure patients 24 . In this study, the need for dose adjustment was essential in 21 patients, but only 11 of cases were adjusted.
Regarding drug-drug interactions, the most common interactive drugs used were furosemide (12.6%), amikacin (2.4%) and non-steroidal anti-inflammatory drugs (NSAID) (4.7%). Two patients were receiving vancomycin, furosemide and amikacin concomitantly. All these medications have been reported to increase the risk of vancomycin-induced nephrotoxicity 27 . Specially, the combination of aminoglycosides with vancomycin has shown to increase renal injury by 20% to 30% 28,29 .
Regarding the appropriate use of vancomycin, a significant variation in the appropriateness of vancomycin use was observed in the three groups based on age (Neonate, Infant, child), P value = 0.015. The most appropriate use was in neonates 85.7%. Dehghan et al. also showed a significant difference in the appropriateness of vancomycin use in three groups based on age (neonates, infants, and children) with P value of 0.017, however, the most appropriate use was observed in infants (68.1%) 32 . The recorded irrational use of vancomycin in this study indicates deficiencies in utilization practices at the level of this hospital and perhaps the entire region. Such practices require further restrictive measures on vancomycin prescribing.
Limitations of the study
One of the major limitations was the poor documentation in the medical records used. Thus, information such as therapeutic monitoring of serum vancomycin concentrations was not available; therefore, we exclude it from the variables to be measured and we recommend that it is essential to document serum concentration levels when using vancomycin.
Conclusion
Our findings confirmed that more than 30% of patients received vancomycin without fulfilling the HICPAC criteria. Insufficient attention to monitor the rate of infusion of vancomycin and serum creatinine, in addition to low rate/lack of requesting 
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